 Winnipeg Free Press | Patent Expirations Hurt Bristol-Myers's Results Wall Street Journal By PETER LOFTUS Bristol-Myers Squibb Co.'s second-quarter profit declined 28%, as sales were eroded by recent patent expirations for top-selling drugs including the anticlotting pill Plavix. The New York drug maker also lowered its forecast of ... Bristol-Myers Second-Quarter Profit Falls on Plavix Sales Drop Generic rivals choke Bristol-Myers 2Q results Bristol sales and earnings fall as generics take a toll |
Wednesday, July 25, 2012
Patent Expirations Hurt Bristol-Myers's Results - Wall Street Journal
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment